PMID- 21770991
OWN - NLM
STAT- MEDLINE
DCOM- 20111019
LR  - 20181201
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 34
IP  - 6
DP  - 2011 Sep
TI  - Systematic review: the association between symptomatic response to proton pump 
      inhibitors and health-related quality of life in patients with gastro-oesophageal 
      reflux disease.
PG  - 618-27
LID - 10.1111/j.1365-2036.2011.04774.x [doi]
AB  - BACKGROUND: Some patients with gastro-oesophageal reflux disease (GERD) 
      experience persistent reflux symptoms on proton pump inhibitor (PPI) therapy. The 
      relationship between persistent reflux symptoms and health-related quality of 
      life (HRQoL) is unclear. AIM: To assess the relationship between persistent 
      reflux symptoms on PPI therapy and HRQoL in patients with GERD. METHODS: 
      Systematic searches were conducted in PubMed and Embase. Eligible studies had to 
      have used psychometrically evaluated patient reported outcome instruments to 
      assess HRQoL. RESULTS: Nine studies were included; supplementary data were 
      obtained for four of these. The effect of persistent reflux symptoms despite PPI 
      therapy on physical HRQoL was assessed in seven studies and that on mental HRQoL 
      in five studies. Compared with patients whose reflux symptoms responded to PPIs, 
      those with persistent symptoms had, on average, 8-16% lower scores for physical 
      health (five studies) and 2-12% lower scores for mental health (three studies). 
      Three studies included data on the effect of baseline HRQoL on subsequent 
      symptomatic response to PPI therapy. Patients with persistent symptoms had 
      clinically relevant lower psychological well-being at baseline compared with 
      those whose symptoms responded to PPIs (average score difference: 7%; two 
      studies). High anxiety levels at baseline seemed to be an important aspect of 
      persistent symptoms. CONCLUSIONS: Persistent reflux symptoms on PPI therapy are 
      associated with reduced physical and mental HRQoL, while reduced mental HRQoL at 
      baseline seems to impair symptomatic response to PPIs. HRQoL may need to be 
      considered alongside reflux symptom frequency and severity when making decisions 
      about disease management.
CI  - (c) 2011 Blackwell Publishing Ltd.
FAU - Becher, A
AU  - Becher A
AD  - Research Evaluation Unit, Oxford PharmaGenesis Ltd, Oxford, UK.
FAU - El-Serag, H
AU  - El-Serag H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20110720
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Gastroesophageal Reflux/*drug therapy/physiopathology
MH  - Humans
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - *Quality of Life
MH  - Severity of Illness Index
EDAT- 2011/07/21 06:00
MHDA- 2011/10/20 06:00
CRDT- 2011/07/21 06:00
PHST- 2011/07/21 06:00 [entrez]
PHST- 2011/07/21 06:00 [pubmed]
PHST- 2011/10/20 06:00 [medline]
AID - 10.1111/j.1365-2036.2011.04774.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2011 Sep;34(6):618-27. doi: 
      10.1111/j.1365-2036.2011.04774.x. Epub 2011 Jul 20.